[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Gulf Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications), Pain Type (Chronic and Acute): Opportunity Analysis and Industry Forecast, 2020–2027

February 2021 | 159 pages | ID: G4CCFA5720D7EN
Allied Market Research

US$ 4,249.00

E-mail Delivery (PDF), Online Subscription, Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The Gulf Pain Management Drugs Market was valued at $851.08 million in 2019, and is projected to reach $1,047.91 million by 2027, registering a CAGR of 3.2%.

Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Moreover, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer.

The length of the pain would range from acute pain for short term to chronic pain for long term. Acute pain is a sudden onset of pain when chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. There are several medicines available, which provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.

Rise in geriatric population is the major factor that drives growth of the Gulf pain management drugs market, as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel the growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

The Gulf pain management drugs market is segmented on the basis of drug class, indication, pain type, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDS), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis and others. On the basis of pain type, the market is segmented into chronic and acute pain.

The key players operating in the Gulf pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, Gulf Pharmaceutical Industries (Julphar), Oman pharmaceutical products Co. LLC, and GlaxoSmithKline Plc.

KEY BENEFITS FOR STAKEHOLDERS
          • This report entails a detailed quantitative analysis along with the current Gulf pain management drugs market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
      • The market forecast is studied from 2020 to 2027.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
          • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
  • By Drug Class
    • NSAIDS
    • Anesthetics
    • Anticonvulsants
    • Antimigraine Agents
    • Antidepressants
    • Opioids
    • Nonnarcotic Analgesics
  • By Indication
    • Arthritic Pain
    • Neuropathic Pain
    • Cancer Pain
    • Chronic Back Pain
    • Postoperative Pain
    • Migraine
    • Fibromyalgia
    • Bone fracture
    • Muscle sprain/strain
    • Acute appendicitis
    • Others
  • By Pain type
    • Chronic pain
    • Acute pain
  • By Country
    • United Arab Emirates
    • Saudi Arabia
    • Oman
    • Others
CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
  1.4.1.Secondary research
  1.4.2.Primary research
  1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
  3.2.1.Top investment pockets
  3.2.2.Top winning strategies
3.3.Top player positioning
3.4.Porter’s five force analysis
3.5.Market dynamics
  3.5.1.Drivers
    3.5.1.1.Rise in incidences of chronic diseases
    3.5.1.2.Favorable regulatory scenario
    3.5.1.3.Increase in geriatric population
  3.5.2.Restraints
    3.5.2.1.Availability of alternative therapies
    3.5.2.2.Drug exploitation
    3.5.2.3.Patent expiration of prescription drugs
  3.5.3.Opportunity
    3.5.3.1.Advancements in drug development
  3.5.4.Impact Analysis
3.6.COVID-19 impact analysis for Gulf Pain Management Drugs

CHAPTER 4:GULF PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

4.1.Overview
  4.1.1.Market size and forecast
4.2.NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
  4.2.1.Key market trends, growth factors, and opportunities
  4.2.2.Market size and forecast
4.3.Anesthetics
  4.3.1.Key market trends, growth factors, and opportunities
  4.3.2.Market size and forecast
4.4.Anticonvulsants
  4.4.1.Key market trends, growth factors, and opportunities
  4.4.2.Market size and forecast
4.5.Antimigraine drug
  4.5.1.Key market trends, growth factors, and opportunities
  4.5.2.Market size and forecast
4.6.Antidepressants
  4.6.1.Key market trends, growth factors, and opportunities
  4.6.2.Market size and forecast
4.7.Opioids
  4.7.1.Key market trends, growth factors, and opportunities
  4.7.2.Market size and forecast
4.8.Non-narcotic analgesics
  4.8.1.Key market trends, growth factors, and opportunities
  4.8.2.Market size and forecast

CHAPTER 5:GULF PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1.Overview
  5.1.1.Market size and forecast
5.2.Arthritic pain
  5.2.1.Market size and forecast
5.3.Neuropathic pain
  5.3.1.Market size and forecast
5.4.Cancer pain
  5.4.1.Market size and forecast
5.5.Chronic back pain
  5.5.1.Market size and forecast
5.6.Post-operative pain
  5.6.1.Market size and forecast
5.7.Migraine
  5.7.1.Market size and forecast
5.8.Fibromyalgia
  5.8.1.Market size and forecast
5.9.Bone fracture
  5.9.1.Market size and forecast
5.10.Muscle sprain/strain
  5.10.1.Market size and forecast
5.11.Acute appendicitis
  5.11.1.Market size and forecast
5.12.Others
  5.12.1.Market size and forecast

CHAPTER 6:PAIN MANAGEMENT DRUGS, BY PAIN TYPE

6.1.Overview
  6.1.1.Market size and forecast
6.2.Chronic pain
  6.2.1.Market size and forecast
6.3.Acute pain
  6.3.1.Market size and forecast

CHAPTER 7:GULF PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY

7.1.Overview
  7.1.1.Market size and forecast
7.2.UAE
  7.2.1.Key market trends and growth opportunities
  7.2.2.Market size and forecast, by drug class
  7.2.3.Market size and forecast, by indication
  7.2.4.Market size and forecast, by pain type
7.3.Saudi Arabia
  7.3.1.Key market trends and growth opportunities
  7.3.2.Market size and forecast, by drug class
  7.3.3.Market size and forecast, by indication
  7.3.4.Market size and forecast, by pain type
7.4.Oman
  7.4.1.Key market trends and growth opportunities
  7.4.2.Market size and forecast, by drug class
  7.4.3.Market size and forecast, by indication
  7.4.4.Market size and forecast, by pain type
7.5.Rest of Gulf countries
  7.5.1.Key market trends and growth opportunities
  7.5.2.Market size and forecast, by drug class
  7.5.3.Market size and forecast, by indication
  7.5.4.Market size and forecast, by pain type

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES
  8.1.1.Company overview
  8.1.2.Company snapshot
  8.1.3.Operating business segments
  8.1.4.Product portfolio
  8.1.5.Business performance
8.2.ELI LILY AND COMPANY
  8.2.1.Company overview
  8.2.2.Company snapshot
  8.2.3.Operating business segments
  8.2.4.Product portfolio
  8.2.5.Business performance
  8.2.6.Key strategic moves and developments
8.3.GLAXOSMITHKLINE PLC (GSK)
  8.3.1.Company overview
  8.3.2.Company snapshot
  8.3.3.Operating business segments
  8.3.4.Product portfolio
  8.3.5.Business performance.
  8.3.6.Key strategic moves and developments
8.4.JOHNSON & JOHNSON
  8.4.1.Company overview
  8.4.2.Company snapshot
  8.4.3.Operating business segments
  8.4.4.Product portfolio
  8.4.5.Business performance
8.5.MERCK & CO., INC.
  8.5.1.Company overview
  8.5.2.Company snapshot
  8.5.3.Operating business segments
  8.5.4.Product portfolio
  8.5.5.Business performance
  8.5.6.Key strategic moves and developments
8.6.MYLAN N.V.
  8.6.1.Company overview
  8.6.2.Company snapshot
  8.6.3.Operating business segments
  8.6.4.Product portfolio
  8.6.5.Business performance
  8.6.6.Key strategic moves and developments
8.7.NOVARTIS INTERNATIONAL AG
  8.7.1.Company overview
  8.7.2.Company snapshot
  8.7.3.Operating business segments
  8.7.4.Product portfolio
  8.7.5.Business performance
  8.7.6.Key strategic moves and developments
8.8.PFIZER INC.
  8.8.1.Company overview
  8.8.2.Company snapshot
  8.8.3.Operating business segments
  8.8.4.Product portfolio
  8.8.5.Business performance
  8.8.6.Key strategic moves and developments
8.9.GULF PHARMACEUTICAL INDUSTRIES (JULPHAR)
  8.9.1.Company overview
  8.9.2.Company snapshot
  8.9.3.Operating business segments
  8.9.4.Product portfolio
  8.9.5.Business performance
8.10.OMAN PHARMACEUTICAL PRODUCTS CO. LLC
  8.10.1.Company overview
  8.10.2.Company snapshot
  8.10.3.Operating business segments
  8.10.4.Product portfolio

LIST OF TABLES

TABLE 01.PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 03.PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 04.GULF PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 05.UAE GULF PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
TABLE 06.UAE GULF PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 07.UAE GULF PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
TABLE 08.SAUDI ARABIA GULF PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
TABLE 09.SAUDI ARABIA GULF PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 10.SAUDI ARABIA GULF PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
TABLE 11.OMAN GULF PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
TABLE 12.OMAN GULF PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 13.OMAN GULF PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
TABLE 14.GULF PAIN MANAGEMENT DRUGS MARKET FOR OTHERS, BY DRUG CLASS, 2019-2027 ($MILLION)
TABLE 15.GULF PAIN MANAGEMENT DRUGS MARKET FOR OTHERS, BY INDICATION, 2019-2027 ($MILLION)
TABLE 16.GULF PAIN MANAGEMENT DRUGS MARKET FOR OTHERS, BY PAIN TYPE, 2019-2027 ($MILLION)
TABLE 17.ABBOTT: COMPANY SNAPSHOT
TABLE 18.ABBOTT: OERATING SEGMENT
TABLE 19.ABBOTT: PRODUCT PORTFOLIO
TABLE 20.ELI LILLY: COMPANY SNAPSHOT
TABLE 21.LILLY: OPERATING SEGMENTS
TABLE 22.ELI LILLY: PRODUCT PORTFOLIO
TABLE 23.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 24.GSK: COMPANY SNAPSHOT
TABLE 25.GSK: OPERATING SEGMENTS
TABLE 26.GSK: PRODUCT PORTFOLIO
TABLE 27.J&J: COMPANY SNAPSHOT
TABLE 28.J&J: OPERATING BUSINESS SEGMENTS
TABLE 29.J&J: PRODUCT PORTFOLIO
TABLE 30.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 31.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 32.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 33.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 34.MYLAN: COMPANY SNAPSHOT
TABLE 35.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 36.MYLAN: PRODUCT PORTFOLIO
TABLE 37.NOVARTIS: COMPANY SNAPSHOT
TABLE 38.NOVARTIS: OPERATING SEGMENTS
TABLE 39.NOVARTIS: PRODUCT PORTFOLIO
TABLE 40.PFIZER: COMPANY SNAPSHOT
TABLE 41.PFIZER: OERATING SEGMENT
TABLE 42.PFIZER: PRODUCT PORTFOLIO
TABLE 43.JULPHAR: COMPANY SNAPSHOT
TABLE 44.JULPHAR: PRODUCT PORTFOLIO
TABLE 45.JULPHAR: COMPANY SNAPSHOT
TABLE 46.JULPHAR: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 05.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 06.TOP PLAYER POSTIONING, 2019
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 09.MODERATE THREAT OF SUBSTITUTES
FIGURE 10.MODEARTE THREAT OF NEW ENTRANTS
FIGURE 11.MODERATE COMPETITIVE OF RIVALRY
FIGURE 12.IMPACT ANALYSIS, GULF PAIN MANAGEMENT DRUGS MARKET
FIGURE 13.GULF PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS, 2019-2027 ($MILLION)
FIGURE 14.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ANAESTHETIC, 2019-2027 ($MILLION)
FIGURE 15.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANTS, 2019-2027 ($MILLION)
FIGURE 16.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ANTI-MIGRAINE AGENTS, 2019-2027 ($MILLION)
FIGURE 17.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANTS, 2019-2027 ($MILLION)
FIGURE 18.GULF PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS, 2019-2027 ($MILLION)
FIGURE 19.GULF PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC ANALGESICS, 2019-2027 ($MILLION)
FIGURE 20.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ARTHRITIC PAIN BY, 2019-2027 ($MILLION)
FIGURE 21.GULF PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN, 2019-2027 ($MILLION)
FIGURE 22.GULF PAIN MANAGEMENT DRUGS MARKET, FOR CANCER PAIN, 2019-2027 ($MILLION)
FIGURE 23.GULF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC BACK PAIN, 2019-2027 ($MILLION)
FIGURE 24.GULF PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN, 2019-2027 ($MILLION)
FIGURE 25.GULF PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINE, 2019-2027 ($MILLION)
FIGURE 26.GULF PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA, 2019-2027 ($MILLION)
FIGURE 27.GULF PAIN MANAGEMENT DRUGS MARKET, FOR BONE FRACTURE, 2019-2027 ($MILLION)
FIGURE 28.GULF PAIN MANAGEMENT DRUGS MARKET, FOR MUSCLE STRAIN/SPRAIN, 2019-2027 ($MILLION)
FIGURE 29.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE APPENDICITIS, 2019-2027 ($MILLION)
FIGURE 30.GULF PAIN MANAGEMENT DRUGS MARKET, FOR OTHERS, 2019-2027 ($MILLION)
FIGURE 31.GULF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN, 2019-2027 ($MILLION)
FIGURE 32.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE PAIN, 2019-2027 ($MILLION)
FIGURE 33.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 37.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 38.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 40.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 41.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 42.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 43.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 44.MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 45.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 46.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 47.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 49.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 50.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 51.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 52.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 53.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 54.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 55.JULPHAR: NET SALES, 2015–2017 ($MILLION)


More Publications